11/25
04:15 pm
oric
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
11/13
12:45 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
11/12
04:05 pm
oric
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
Low
Report
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
11/4
04:15 pm
oric
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
11/4
08:19 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Medium
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
11/1
04:30 pm
oric
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/31
07:36 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $20.00 price target on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $20.00 price target on the stock.
10/23
07:00 am
oric
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Medium
Report
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
10/16
08:05 am
oric
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors
Low
Report
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors
10/9
04:15 pm
oric
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Low
Report
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
10/4
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)